The U.S. Food and Drug Administration (FDA) has approved bluebird bio’s Zynteglo (betibeglogene autotemcel), also known as beti-cel: a one-time gene therapy custom-designed to treat the underlying genetic cause of beta thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Moderna’s next-gen COVID-19 booster becomes first authorized Omicron-specific bivalent vaccine
COVID-19
Resilience and Mayo Clinic create biomanufacturing partnership for rare and complex conditions
Antibody-Drug Conjugates
Teva bullish ahead of 2-step biosimilar attack on AbbVie’s blockbuster Humira
Biosimilars
Sartorius to acquire Albumedix for $502m
Cell & Gene Therapies
